Earlier is a hypothesis with consequences
Finding a signal earlier can feel like an unquestionable advantage. Screening research has to ask what happens next: whether diagnosis and treatment help, whether unnecessary investigations cause harm, and whether outcomes improve for the people offered the test.
A promising detection technology can answer one part of that question while leaving others open. Sensitivity, specificity, and a plausible biological signal do not by themselves establish a reduction in cancer deaths.
What PATHFINDER showed
PATHFINDER was a prospective cohort study of a multicancer early-detection blood test in adults aged 50 or older without symptoms of cancer. Among 6,621 participants with analyzable results, 92 had a cancer signal. Cancer was diagnosed in 35 of those participants; 57 had no cancer diagnosis. [1]
The study also followed the diagnostic work prompted by the result. That is an essential part of evaluating screening. It was a feasibility study, not a randomized demonstration that offering the test improves survival.
The person lives through the uncertainty
A positive result starts a period of investigation. A negative result can also be misinterpreted if it is taken to rule out every cancer. The relevant evidence includes the whole pathway: time to resolution, imaging, procedures, complications, and whether the eventual diagnosis changes care usefully.
Lead-time bias is another concern. Counting survival from an earlier diagnosis can lengthen the measured interval even if the time of death is unchanged. A screening program therefore needs outcomes that address the benefit it promises.
A clearer decision
Before adding a test, a clinical conversation should identify the purpose, the expected follow-up, the limits of reassurance, and how it fits with established screening and individual risk. Symptoms require their own assessment; a screening test is not a substitute.
The promise of earlier detection is real enough to test rigorously. The strongest future result will connect a technically impressive signal to a demonstrable improvement in people's lives, with the burden of false alarms and unnecessary treatment included in the account.
Sources & reading scope
- Deb Schrag, Tomasz M Beer, Charles H McDonnell, et al. Blood-based tests for multicancer early detection (PATHFINDER): a prospective cohort study. Lancet (London, England). 2023 Oct 07;402(10409):1251-1260. doi:10.1016/S0140-6736(23)01700-2. PMID:37805216.
Primary publication record and abstract consulted; not a comprehensive full-text appraisal.